Literature DB >> 33505496

Effect and Molecular Mechanisms of Jiedu Recipe on Hypoxia-Induced Angiogenesis after Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma.

Wanfu Lin1, Huan Wang1, Maofeng Zhong2, Shasha Yu1, Shasha Zhao1, Shufang Liang1, Juan Du1, Binbin Cheng1, Wei Gu1, Changquan Ling1.   

Abstract

Transcatheter arterial chemoembolization (TACE) is one of the effective treatment methods for hepatocellular carcinoma (HCC) in middle and late phases. However, TACE-induced hypoxia may promote the angiogenesis and section of some cytokines, such as IL-8, and, thereby, lead to tumor metastasis. Therefore, we investigated the effect of Jiedu Recipe (JR), which has been demonstrated as an effective Traditional Chinese Medicine (TCM) recipe on HCC, on TACE-induced cytokines upregulation and hypoxia-induced angiogenesis. A total of 88 hepatocellular carcinoma (HCC) patients treated with TACE were enrolled and divided into a JR group or control group. TACE induced significant increases of neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), IL-1β, IL-2R, IL-6, and IL-8. JR treatment significantly inhibited the elevation of IL-8 compared with control. In vitro, JR significantly inhibited the hypoxia-induced overexpression of IL-8, HIF-1α, and VEGF mRNA in Huh 7 cells. ELISA assay demonstrated the effect of JR on IL-8 expression. Both hypoxia and IL-8 may promote angiogenesis which was suppressed by JR. Western blot showed that IL-8 upregulated the expression of phosphorylation of AKT, ERK, NF-κB, and VEGFR, which were inhibited by JR. On the other hand, effects of IL-8 on the increase of p-AKT and p-ERK were also blocked by LY294002 and U0126, respectively. In conclusion, our results indicated that JR may inhibit hypoxia-induced angiogenesis through suppressing IL-8/HIF-1α/PI3K and MAPK/ERK pathways after TACE in HCC patients.
Copyright © 2021 Wanfu Lin et al.

Entities:  

Year:  2021        PMID: 33505496      PMCID: PMC7815394          DOI: 10.1155/2021/6529376

Source DB:  PubMed          Journal:  Evid Based Complement Alternat Med        ISSN: 1741-427X            Impact factor:   2.629


  41 in total

1.  Inhibition of tumour angiogenesis and growth by small hairpin HIF-1α and IL-8 in hepatocellular carcinoma.

Authors:  Sung Hoon Choi; Oh-Joon Kwon; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Seung Up Kim; Simon Weonsang Ro; Kyung Sik Kim; Jeon Han Park; Seungtaek Kim; Chae-Ok Yun; Kwang-Hyub Han
Journal:  Liver Int       Date:  2013-12-09       Impact factor: 5.828

2.  Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Authors:  Riccardo Lencioni; Josep M Llovet; Guohong Han; Won Young Tak; Jiamei Yang; Alfredo Guglielmi; Seung Woon Paik; Maria Reig; Do Young Kim; Gar-Yang Chau; Angelo Luca; Luis Ruiz Del Arbol; Marie-Aude Leberre; Woody Niu; Kate Nicholson; Gerold Meinhardt; Jordi Bruix
Journal:  J Hepatol       Date:  2016-01-22       Impact factor: 25.083

3.  The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study.

Authors:  Yang Yu; Qingbo Lang; Zhe Chen; Bai Li; Chaoqin Yu; Dezeng Zhu; Xiaofeng Zhai; Changquan Ling
Journal:  Cancer       Date:  2009-11-15       Impact factor: 6.860

4.  Change in inflammatory cytokine profiles after transarterial chemotherapy in patients with hepatocellular carcinoma.

Authors:  Min Ju Kim; Jeong Won Jang; Byong Sun Oh; Jung Hyun Kwon; Kyu Won Chung; Hyun Suk Jung; Dong Wook Jekarl; Seungok Lee
Journal:  Cytokine       Date:  2013-09-12       Impact factor: 3.861

Review 5.  Oxygen-dependent and -independent regulation of HIF-1alpha.

Authors:  Yang-Sook Chun; Myung-Suk Kim; Jong-Wan Park
Journal:  J Korean Med Sci       Date:  2002-10       Impact factor: 2.153

6.  Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma.

Authors:  Hetong Zhao; Xiaofeng Zhai; Zhe Chen; Xuying Wan; Lanyu Chen; Feng Shen; Changquan Ling
Journal:  Oncotarget       Date:  2017-07-11

7.  HIF-1α promotes the migration and invasion of hepatocellular carcinoma cells via the IL-8-NF-κB axis.

Authors:  Wenming Feng; Tao Xue; Sanxiong Huang; Qilin Shi; Chengwu Tang; Ge Cui; Guanghui Yang; Hui Gong; Huihui Guo
Journal:  Cell Mol Biol Lett       Date:  2018-05-31       Impact factor: 5.787

Review 8.  How to define transarterial chemoembolization failure or refractoriness: a European perspective.

Authors:  Jean-Luc Raoul; Marine Gilabert; Gilles Piana
Journal:  Liver Cancer       Date:  2014-05       Impact factor: 11.740

9.  Inflammatory markers C-reactive protein and PLR in relation to HCC characteristics.

Authors:  Aslı Suner; Brian I Carr; Hikmet Akkiz; Oguz Uskudar; Sedef Kuran; Yaman Tokat; Salih Tokmak; Tugsan Ballı; Abdulalh Ulku; Tolga AkCam; Anıl Delik; Burcu Arslan; Figen Doran; Kendal YalCın; Nazım Ekinci; Sezai Yilmaz; Ayşegul Ozakyol; Mehmet Yücesoy; Halil Ibrahim BahCeci; Kamil Yalcın Polat; Halis Şimsek; Necati Ormeci; Abdulalh Sonsuz; Mehmet Demir; Murat KılıC; Ahmet Uygun; Ali Demir; Engin Altıntas; Gokhan Karakulah; Tuncer Temel; Ahmet Bektas
Journal:  J Transl Sci       Date:  2018-06-22

10.  Upregulation of hypoxia-inducible factor 1α mRNA expression was associated with poor prognosis in patients with hepatocellular carcinoma.

Authors:  Wei Cheng; Ziwei Cheng; Zongguo Yang; Dongwei Xing; Minguang Zhang
Journal:  Onco Targets Ther       Date:  2019-08-09       Impact factor: 4.147

View more
  4 in total

Review 1.  Co-Targeting Tumor Angiogenesis and Immunosuppressive Tumor Microenvironment: A Perspective in Ethnopharmacology.

Authors:  Jianbo Zhou; Li Wang; Cheng Peng; Fu Peng
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

Review 2.  Therapeutic potential of traditional Chinese medicine for vascular endothelial growth factor.

Authors:  Yijia Mao; Lingkai Meng; Huayi Liu; Yuting Lu; Kuo Yang; Guangze Ouyang; Yanran Ban; Shuang Chen
Journal:  J Zhejiang Univ Sci B       Date:  2022-05-15       Impact factor: 5.552

Review 3.  Current Perspective of Traditional Chinese Medicines and Active Ingredients in the Therapy of Hepatocellular Carcinoma.

Authors:  Yuyao Li; Yue Li; Jinghao Zhang; Longshan Ji; Man Li; Xuehua Sun; Hai Feng; Zhuo Yu; Yueqiu Gao
Journal:  J Hepatocell Carcinoma       Date:  2022-02-09

4.  Comparative effectiveness of interventional therapeutic modalities for unresectable hepatocellular carcinoma: A systematic review and network meta-analysis.

Authors:  Xin-Long Chen; Hai-Chuan Yu; Qi-Gang Fan; Qi Yuan; Wen-Kai Jiang; Shao-Zhen Rui; Wen-Ce Zhou
Journal:  Oncol Lett       Date:  2022-08-31       Impact factor: 3.111

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.